|
 |
Nome commerciale |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Humalog |
Africa del Sud, Arabia Saudita, Argentina, Australia, Austria, Belgio, Brasile, Canada, Chile, Colombia, Croazia, Danimarca, Ecuador, Emirati Arabi Uniti, Finlandia, Francia, Germania, Giappone, Gran Bretagna, Grecia, Irlanda, Islanda, Italia, Lussemburgo, Malaysia, Marocco, Messico, Norvegia, nuova Zelanda, Paesi Bassi, Perù, Polonia, Portogallo, Romania, Slovenia, Spagna, Stati Uniti d’America, Svezia, Svizzera, Turchia, Ungheria, Venezuela |
|
|
 |
 |
Bibliografia : Insulin lyspro |
|
|
tipo |
pubblicazione |
| 2269 |
Rivista |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3149 |
Rivista |
DeFelippis MR, Bell MA, Heyob JA, Storms SM.
In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion.
Diabetes Tech and Ther 2006 ; 8, 3: 358-368. |
| 3249 |
Rivista |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 4433 |
Rivista |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4650 |
Laboratorio |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 5045 |
Laboratorio |
Humalog 100 UI/ml, solution injectable en flacon - Résumé des caractéristiques du produit.
Eli Lilly 2006 |
|
|
